ReviewJournal of food and drug analysis2026
Emerging antifungal strategies against Candida albicans using metal-organic frameworks and novel therapeutics: Opportunities and challenges.
Review in Journal of food and drug analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida albicans is an opportunistic fungal pathogen responsible for infections ranging from superficial mucosal disease to life-threatening systemic candidiasis, particularly in immunocompromised hosts. Its pathogenicity is enhanced by morphological plasticity, biofilm formation, and immune evasion, contributing to antifungal resistance. Limitations of existing antifungals have driven interest in emerging therapeutics. This review highlights strategies including metal-organic frameworks (MOFs), host-directed therapies (HDTs), CRISPR-Cas9 gene editing, and phytochemicals. MOFs offer high drug-loading capacity, controlled release, and enhanced penetration into biofilms, showing promise against drug-resistant strains. Selected phytochemicals demonstrate inhibitory effects on virulence traits such as hyphal formation and enzyme secretion. CRISPR-Cas9 enables functional genomic studies to identify and disrupt key pathogenicity genes, while HDTs aim to boost host immune responses. Additionally, the potential role of gut microbiota modulation in controlling C. albicans colonization is discussed. By integrating mechanistic insights with translational perspectives, this review provides a concise overview of emerging antifungal strategies, opportunities, and challenges with the potential to overcome current therapeutic limitations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.